EP Patent

EP1487829A1 — Thiadiazolylpiperazine derivatives useful for treating or preventing pain

Assigned to Euro Celtique SA · Expires 2004-12-22 · 21y expired

What this patent protects

A compound of formula: (wherein X, R<SUP>1</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, and R<SUP>5 </SUP>are disclosed herein) or a pharmaceutically acceptable salt thereof (a "Thiadiazolylpiperazine Compound"), pharmaceutical comp…

USPTO Abstract

A compound of formula: (wherein X, R<SUP>1</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, and R<SUP>5 </SUP>are disclosed herein) or a pharmaceutically acceptable salt thereof (a "Thiadiazolylpiperazine Compound"), pharmaceutical compositions comprising a Thiadiazolylpiperazine Compound, and methods for treating or preventing, e.g., pain, depression and anxiety, in a patient comprising administering to a patient in need thereof an effective amount of a Thiadiazolylpiperazine Compound are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP1487829A1
Jurisdiction
EP
Classification
—
Expires
2004-12-22
Drug substance claim
No
Drug product claim
No
Assignee
Euro Celtique SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.